Tvardi Therapeutics (TVRD) Competitors

Iovance Biotherapeutics (NASDAQ:IOVA) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership.

Do analysts prefer IOVA or TVRD?

Iovance Biotherapeutics currently has a consensus target price of $11.90, indicating a potential upside of 342.38%. Tvardi Therapeutics has a consensus target price of $64.25, indicating a potential upside of 129.06%. Given Iovance Biotherapeutics' higher probable upside, equities research analysts clearly believe Iovance Biotherapeutics is more favorable than Tvardi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	1 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.36
Tvardi Therapeutics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more risk and volatility, IOVA or TVRD?

Iovance Biotherapeutics has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500. Comparatively, Tvardi Therapeutics has a beta of 0.21, meaning that its stock price is 79% less volatile than the S&P 500.

Do insiders and institutionals have more ownership in IOVA or TVRD?

77.0% of Iovance Biotherapeutics shares are owned by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are owned by institutional investors. 10.3% of Iovance Biotherapeutics shares are owned by company insiders. Comparatively, 3.1% of Tvardi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Is IOVA or TVRD more profitable?

Iovance Biotherapeutics has a net margin of -161.44% compared to Tvardi Therapeutics' net margin of -678.79%. Iovance Biotherapeutics' return on equity of -52.87% beat Tvardi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-161.44%	-52.87%	-41.31%
Tvardi Therapeutics	-678.79%	-565.83%	-66.71%

Does the media prefer IOVA or TVRD?

In the previous week, Iovance Biotherapeutics had 18 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 20 mentions for Iovance Biotherapeutics and 2 mentions for Tvardi Therapeutics. Iovance Biotherapeutics' average media sentiment score of 0.72 beat Tvardi Therapeutics' score of 0.34 indicating that Iovance Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	7 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Tvardi Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has better valuation and earnings, IOVA or TVRD?

Tvardi Therapeutics has lower revenue, but higher earnings than Iovance Biotherapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$164.07M	5.93	-$372.18M	-$1.23	-2.19
Tvardi Therapeutics	$7.14M	36.85	-$70.87M	N/A	N/A

Summary

Iovance Biotherapeutics beats Tvardi Therapeutics on 11 of the 14 factors compared between the two stocks.